The median follow-up time of de novo CD5+ DLBCL and CD5- DLBCL patients was 13 months (ranging from 1 to 163) and 43 months (ranging from 0 to 261), respectively. The gene discussed is CD5; the disease is diffuse large B-cell lymphoma.